CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia
The findings of the study address the issue of tumor antigen evasion in the treatment of AML, circumvent certain constraints associated with autologous CAR-T cell therapy, and offer novel insights and strategies for managing AML.
Authors
- Qizhong Lu
- Huaqing Lu
- Zhengyu Yu (ORCID: https://orcid.org/0000-0002-8888-4570)
- Nian Yang (ORCID: https://orcid.org/0000-0002-5269-7837)
- Aiping Tong (ORCID: https://orcid.org/0000-0002-3392-5443)
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Jia Li (ORCID: https://orcid.org/0000-0002-2286-1704)
- Zeng Wang (ORCID: https://orcid.org/0000-0002-3274-4296)
- Yongdong Chen
- Zongliang Zhang (ORCID: https://orcid.org/0000-0003-1859-0451)
- Zhixiong Zhu
- Hexian Li (ORCID: https://orcid.org/0000-0002-0445-8014)
- Zhiguo Wu (ORCID: https://orcid.org/0000-0001-8758-785X)
Institutions
- Sichuan University (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1097/cm9.0000000000003588
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09